November 26, 2026

BSE Limited **Code: 532321**
P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited **Code: Zyduslife**
Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Re.: Update

Dear Sir / Madam,

Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company's subsidiary Zydus Therapeutics Inc., USA has received a Complete Response Letter ("**CRL**") from the U.S. Food and Drug Administration ("**USFDA**") in relation to the New Drug Application ("**NDA**") for saroglitazar.

The CRL relates to the Company's ongoing review of the resolution plan addressing observations from October 2026 inspection of the Moraiya facility.

The Company is engaged in addressing the observations and remains committed to working closely with the USFDA to complete the necessary actions and support the continued review of the application.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Yours faithfully,
For, **Zydus Lifesciences Limited**

DHAVAL NARENDRA SONI
Digitally signed by DHAVAL NARENDRA SONI
Date: 2026.11.26 15:39:22 +05'30'

Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCS7063